Evidence map›Paper›PMID 41391039›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Mechanism-Driven Screening of Membrane-Targeting and Pore-Forming Antimicrobial Peptides.

Jiaxuan Li, Chenguang Yang, Ruihan Dong, Juan Francisco Bada Juarez, Lei Wang, Maximilian Emanuel Wettstein, Dali Wang, Chan Cao, Ying Lu, Chen Song

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Mechanism-Driven Screening of Membrane-Targeting and Pore-Forming Antimicrobial Peptides.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiaxuan LiCenter for Quantitative Biology, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Chenguang YangBeijing National Laboratory for Condensed Matter Physics, Institute of Physics, Chinese Academy of Sciences, Beijing, 100190, China.
Ruihan DongCenter for Quantitative Biology, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Juan Francisco Bada JuarezInstitute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, 1015, Switzerland.
Lei WangCenter for Quantitative Biology, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Maximilian Emanuel WettsteinInstitute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, 1015, Switzerland.
Dali WangCenter for Quantitative Biology, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Chan CaoDepartment of Inorganic and Analytical Chemistry, University of Geneva, Geneva, 1211, Switzerland.
Ying LuBeijing National Laboratory for Condensed Matter Physics, Institute of Physics, Chinese Academy of Sciences, Beijing, 100190, China.
Chen SongCenter for Quantitative Biology, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.ORCID https://orcid.org/0000-0001-9730-3216

Funding

Dementia Research Switzerland - Synapsis Foundation 2019-CDA02Dementia Research Switzerland - Synapsis Foundation 2022-CDA03Frontier Innovation Fund of Peking University Chengdu Academy for Advanced Interdisciplinary BiotechnologiesNational Key R&D Program of China 2024YFA0916800Natural Science Foundation of China T2321001Novartis Foundation for Medical-Biological ResearchSwiss National Science Foundation PR00P3_193090
6 · The paper itself

Abstract

The rise of antibiotic resistance has created an urgent need for the discovery of new antimicrobial peptides (AMPs), prompting various screening strategies. However, the mechanisms of action of AMPs are often overlooked during screening and optimization. Here, a mechanism-driven screening approach is introduced using machine learning-based computational models to identify peptide sequences that target bacterial membranes and form pores. From the metaproteomes of poison frogs, African clawed frogs, and human skin, seven peptides are identified and validated, each exhibiting antimicrobial activity with minimal hemolysis and cytotoxicity. These peptides demonstrated membrane disruption in liposome leakage assays, with three showing broad-spectrum activity against Gram-positive and Gram-negative bacteria. Single-molecule experiments confirmed peptide oligomerization on membranes, while electrophysiological measurements verified pore formation by the three broad-spectrum AMPs, suggesting a correlation between pore-forming ability and broad-spectrum antimicrobial activity. This approach offers a promising mechanism-driven strategy for discovering new antimicrobial agents to combat antibiotic resistance.

Indexed as

Antimicrobial PeptidesCell MembraneAnimalsAnti-Bacterial AgentsGram-Negative BacteriaHemolysisHumansMachine LearningMicrobial Sensitivity TestsPore Forming Cytotoxic ProteinsAnti-Bacterial AgentsAntimicrobial PeptidesPore Forming Cytotoxic Proteinsantimicrobial peptidemachine learningmembraneporescreening

Identifiers

PMID41391039
PMCPMC12904036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.